More tools:Markets·Screener·Research·Chat

Xenetic Biosciences, Inc. (XBIO) Financial Statements

Xenetic Biosciences, Inc.
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG0028WJY38
XNAS · usd
4.28▼ 0.39 (-8.35%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA—
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close4.67
Day's Range4.00 – 4.76
52-Week Range1.90 – 13.93
Volume85.4K
Avg Volume62.6K
Share Statistics
Shares Outstanding
Employees2
ExchangeXNAS
Listed2012-05-16
Share count as of July 31, 2026
Loading Income Statement…
Key questions about Xenetic Biosciences, Inc. (XBIO)
What is Xenetic Biosciences, Inc.'s Market Cap?
Xenetic Biosciences, Inc.'s Market Cap is $10.0M, based on as-reported figures from SEC (XBRL) filings.
What is Xenetic Biosciences, Inc.'s Enterprise Value?
Xenetic Biosciences, Inc.'s Enterprise Value is $3.6M, based on as-reported figures from SEC (XBRL) filings.
What is Xenetic Biosciences, Inc.'s Price / Sales?
Xenetic Biosciences, Inc.'s Price / Sales is 3.1×, based on as-reported figures from SEC (XBRL) filings.
What is Xenetic Biosciences, Inc.'s EV / Revenue?
Xenetic Biosciences, Inc.'s EV / Revenue is 1.1×, based on as-reported figures from SEC (XBRL) filings.
What is Xenetic Biosciences, Inc.'s Revenue (TTM)?
Xenetic Biosciences, Inc.'s Revenue (TTM) is $3.3M, based on as-reported figures from SEC (XBRL) filings.
What is Xenetic Biosciences, Inc.'s Net Income (TTM)?
Xenetic Biosciences, Inc.'s Net Income (TTM) is -$2.5M, based on as-reported figures from SEC (XBRL) filings.
What is Xenetic Biosciences, Inc.'s Diluted EPS (TTM)?
Xenetic Biosciences, Inc.'s Diluted EPS (TTM) is -1.06, based on as-reported figures from SEC (XBRL) filings.
What is Xenetic Biosciences, Inc.'s Net Debt?
Xenetic Biosciences, Inc.'s Net Debt is -$6.5M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Revenue
YoY growth+12.0%+36.0%+18.1%+67.2%
Operating costs and expenses:
Research and development
General and administrative
Total operating costs and expenses
% of revenue-247.1%-162.2%-181.3%-153.0%
Loss from operations
% of revenue-147.1%-62.2%-81.3%-53.0%
Other income (expense):
Non-Operating Income (Expense)
Interest and Dividend Income (Non-Bank)——
Total other income
Net loss
% of revenue-140.7%-56.6%-75.6%-49.7%
Earnings Per Share (Basic)—
Earnings Per Share (Diluted)—